GNFTF News and Press, Genfit Ord From 03/14/19

Loos, France-based Genfit S.A. ( OTCPK:GNFTF +2.6% ) has filed a preliminary prospectus for an initial public offering (IPO) of 5M American Depositary Shares (ADSs), applying for the ticker symbol "GNFT." More news on: Genfit SA, Healthcare stocks news, IPO News, Stocks on the move, ...

Nano cap Conatus Pharmaceuticals ( CNAT +22.2% ) is up on more than a 4x surge in volume. Shares have rallied  43%  this week. More news on: Conatus Pharmaceuticals Inc., Madrigal Pharmaceuticals, Inc., Viking Therapeutics, Inc., Healthcare stocks news, Stocks on the move, ...

With one product candidate at phase 3 of development, Genfit (GNFTF) should interest institutional investors quite a bit. The results are expected by the end of 2019, which the market should remember well. Keep in mind that beneficial results could make the share price increase quite a bit. Ha...

Quick Take Genfit S.A. ( GNFT ) intends to raise $100 million in an IPO of ADSs representing ordinary shares, according to an F-1 registration statement . The firm is developing treatment candidates for non-alcoholic steatohepatitis [NASH] conditions. GNFT says it expects results from i...

Intercept's data in NASH fibrosis get a muted reception Intercept Pharmaceuticals ( ICPT ) last week announced data from its pivotal REGENERATE PhIII trial evaluating lead drug obeticholic acid ('OCA'), currently marketed as OCALIVA , in patients with liver fibrosis due to NASH. OCA has r...

Background NASH, or nonalcoholic steatohepatitis, has only been widely recognized as a disease for a short time. It may be more than one disease, given that it is defined as fatty, inflamed liver that is not due to alcohol abuse. Being a "not" condition implies that sub-types may exist. Ev...

Intercept Pharmaceuticals ( ICPT ) recently reported interim results from its phase 3 REGENERATE study. It noted that it had met on one co-primary endpoint, but failed on another. The company will be able to file for FDA and EMA approval, but a few issues associated with the drug may not a...

Gilead Sciences (GILD) has a very tough road ahead after its latest earnings report. The earnings for the fourth quarter were mixed, but the company needs to take drastic action to redeem itself. The revenue may have come in over expectations, but it won't be long until Gilead finds itself i...

My previous article forecast problems for selonsertib, as new research indicates that this drug targets mouse-specific pathways that are not present in humans. NASH cirrhosis trials continue to struggle. Intercept’s Ocaliva, a “NASH cirrhosis” drug candidate, is haile...

Editor's note: Seeking Alpha is proud to welcome Richelle Cutler-Strom as a new contributor. It's easy to become a Seeking Alpha contributor and earn money for your best investment ideas. Active contributors also get free access to the SA PRO archive. Click here to find out more » The...